Oligoadenylate synthetase 1 displays dual antiviral mechanisms in driving translational shutdown and protecting interferon production.

SARS-CoV-2 West Nile virus antiviral mechanism interferon interferon-stimulated genes oligoadenylate synthetase

Journal

Immunity
ISSN: 1097-4180
Titre abrégé: Immunity
Pays: United States
ID NLM: 9432918

Informations de publication

Date de publication:
23 Feb 2024
Historique:
received: 15 06 2023
revised: 15 11 2023
accepted: 05 02 2024
medline: 1 3 2024
pubmed: 1 3 2024
entrez: 29 2 2024
Statut: aheadofprint

Résumé

In response to viral infection, how cells balance translational shutdown to limit viral replication and the induction of antiviral components like interferons (IFNs) is not well understood. Moreover, how distinct isoforms of IFN-induced oligoadenylate synthetase 1 (OAS1) contribute to this antiviral response also requires further elucidation. Here, we show that human, but not mouse, OAS1 inhibits SARS-CoV-2 replication through its canonical enzyme activity via RNase L. In contrast, both mouse and human OAS1 protect against West Nile virus infection by a mechanism distinct from canonical RNase L activation. OAS1 binds AU-rich elements (AREs) of specific mRNAs, including IFNβ. This binding leads to the sequestration of IFNβ mRNA to the endomembrane regions, resulting in prolonged half-life and continued translation. Thus, OAS1 is an ARE-binding protein with two mechanisms of antiviral activity: driving inhibition of translation but also a broader, non-canonical function of protecting IFN expression from translational shutdown.

Identifiants

pubmed: 38423012
pii: S1074-7613(24)00077-3
doi: 10.1016/j.immuni.2024.02.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests M.S.D. is a consultant for Inbios, Journal of Virol. Biotechnology, Ocugen, Topspin, Moderna, and Merck. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Journal of Virol. Biotechnology, Emergent BioSolutions, and Moderna.

Auteurs

Munesh K Harioudh (MK)

Cancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Microbiology and Molecular Genetics, Pittsburgh, PA, USA.

Joseph Perez (J)

Cancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Microbiology and Molecular Genetics, Pittsburgh, PA, USA.

Zhenlu Chong (Z)

Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Sharmila Nair (S)

Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Lomon So (L)

Department of Immunology, School of Medicine, University of Washington, Seattle, WA, USA; Division of Immunology, Benaroya Research Institute, Seattle, WA, USA.

Kevin D McCormick (KD)

Cancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Microbiology and Molecular Genetics, Pittsburgh, PA, USA.

Arundhati Ghosh (A)

Cancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Microbiology and Molecular Genetics, Pittsburgh, PA, USA.

Lulu Shao (L)

Cancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Microbiology and Molecular Genetics, Pittsburgh, PA, USA.

Rashmi Srivastava (R)

Cancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Microbiology and Molecular Genetics, Pittsburgh, PA, USA.

Frank Soveg (F)

Department of Immunology, School of Medicine, University of Washington, Seattle, WA, USA.

Thomas S Ebert (TS)

Department of Biochemistry, Ludwig Maximilians Universität, Munich, Germany.

Maninjay K Atianand (MK)

Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Veit Hornung (V)

Department of Biochemistry, Ludwig Maximilians Universität, Munich, Germany.

Ram Savan (R)

Department of Immunology, School of Medicine, University of Washington, Seattle, WA, USA.

Michael S Diamond (MS)

Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.

Saumendra N Sarkar (SN)

Cancer Virology Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Microbiology and Molecular Genetics, Pittsburgh, PA, USA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: saumen@pitt.edu.

Classifications MeSH